DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) issued an update on its FY22 earnings guidance on Tuesday morning. The company provided EPS guidance of $2.35-2.55 for the period, compared to the consensus EPS estimate of $2.79. The company issued revenue guidance of $4.1-4.2 billion, compared to the consensus revenue estimate of $4.24 billion.DENTSPLY SIRONA also updated its FY 2022 guidance to $2.35-$2.55 EPS.
XRAY stock traded down $2.71 during midday trading on Tuesday, hitting $36.54. The company’s stock had a trading volume of 254,029 shares, compared to its average volume of 2,160,024. DENTSPLY SIRONA has a 12 month low of $39.09 and a 12 month high of $69.54. The company has a quick ratio of 1.12, a current ratio of 1.55 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $7.87 billion, a price-to-earnings ratio of 20.44, a price-to-earnings-growth ratio of 2.49 and a beta of 0.94. The company has a 50 day moving average of $46.88 and a two-hundred day moving average of $51.67.
DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.52 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.04). DENTSPLY SIRONA had a net margin of 9.90% and a return on equity of 12.51%. The company had revenue of $9.67 billion for the quarter, compared to analysts’ expectations of $982.05 million. During the same quarter in the previous year, the company posted $0.72 EPS. The business’s quarterly revenue was up 841.1% on a year-over-year basis. On average, analysts anticipate that DENTSPLY SIRONA will post 2.6 earnings per share for the current fiscal year.
XRAY has been the subject of a number of recent analyst reports. Barrington Research cut their price objective on DENTSPLY SIRONA from $72.00 to $53.00 in a research report on Wednesday, April 20th. Morgan Stanley cut their price objective on DENTSPLY SIRONA from $62.00 to $52.00 and set an overweight rating on the stock in a report on Wednesday, April 20th. Credit Suisse Group cut their price target on DENTSPLY SIRONA from $68.00 to $67.00 and set an outperform rating on the stock in a report on Tuesday, March 1st. William Blair downgraded DENTSPLY SIRONA from an outperform rating to a market perform rating in a report on Tuesday, April 19th. Finally, HC Wainwright decreased their price objective on DENTSPLY SIRONA from $58.00 to $48.00 and set a hold rating for the company in a research report on Friday, April 22nd. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, DENTSPLY SIRONA presently has a consensus rating of Hold and an average price target of $53.11.
In other news, Director Eric Brandt sold 6,900 shares of the company’s stock in a transaction on Tuesday, May 3rd. The shares were sold at an average price of $39.71, for a total value of $273,999.00. Following the transaction, the director now directly owns 35,155 shares of the company’s stock, valued at $1,396,005.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.69% of the company’s stock.
Large investors have recently modified their holdings of the stock. Morgan Stanley boosted its holdings in DENTSPLY SIRONA by 16.1% in the second quarter. Morgan Stanley now owns 607,754 shares of the medical instruments supplier’s stock worth $38,445,000 after purchasing an additional 84,088 shares in the last quarter. Barclays PLC raised its position in shares of DENTSPLY SIRONA by 21.0% during the fourth quarter. Barclays PLC now owns 430,984 shares of the medical instruments supplier’s stock valued at $24,043,000 after buying an additional 74,810 shares during the last quarter. California State Teachers Retirement System raised its position in DENTSPLY SIRONA by 2.3% in the fourth quarter. California State Teachers Retirement System now owns 392,340 shares of the medical instruments supplier’s stock worth $21,889,000 after purchasing an additional 8,995 shares in the last quarter. Comerica Bank raised its position in DENTSPLY SIRONA by 15.1% in the fourth quarter. Comerica Bank now owns 59,175 shares of the medical instruments supplier’s stock worth $3,120,000 after purchasing an additional 7,764 shares in the last quarter. Finally, LPL Financial LLC boosted its holdings in shares of DENTSPLY SIRONA by 31.1% in the 4th quarter. LPL Financial LLC now owns 34,964 shares of the medical instruments supplier’s stock worth $1,951,000 after acquiring an additional 8,291 shares in the last quarter. Hedge funds and other institutional investors own 94.79% of the company’s stock.
About DENTSPLY SIRONA (Get Rating)
DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.
- Get a free copy of the StockNews.com research report on DENTSPLY SIRONA (XRAY)
- If PetMeds Is A Good Buy There Will Be A Better Signal
- Insiders Buy Occidental Petroleum Ahead Of Q1 Earnings
- High-Yield Deep-Value LCI Industries Exceeds All Expectations
- Shopify (NYSE: SHOP) Approaches Key Support Level
- The Low In Lordstown Motors May Not Be The Last
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.